How India Exports Fexofenadine to the World

In the United States, fexofenadine is approved for use in various formulations, including oral tablets and suspensions. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for fexofenadine hydrochloride, indicating a competitive generic market. Notably, Impax Laboratories received approval for their ANDA 076298 for Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release Tablets (60 mg/120 mg) on September 3, 2010.

The substantial number of approved ANDAs reflects the active participation of numerous Indian exporters in the U.S. market. However, it is crucial for exporters to remain vigilant regarding FDA import alerts and compliance requirements to ensure uninterrupted market access.

In the European Union, fexofenadine is subject to marketing authorization by national competent authorities. The European Medicines Agency (EMA) conducted a Periodic Safety Update Report Single Assessment (PSUSA) for fexofenadine, resulting in a variation to the terms of the marketing authorization in January 2023. (ema.europa.eu) This underscores the importance of ongoing pharmacovigilance and compliance with EU Good Manufacturing Practice (GMP) requirements.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a Class 4 Medicines Defect Notification in August 2025 concerning an error with the European Article Number (EAN) barcode on certain batches of fexofenadine hydrochloride 120 mg film-coated tablets. (gov.uk) This highlights the necessity for exporters to maintain stringent quality control measures to meet UK regulatory standards.

Fexofenadine is included in the World Health Organization's Model List of Essential Medicines, reflecting its recognized importance in global health. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for market acceptance and regulatory compliance.

In India, fexofenadine is classified under Schedule H, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO) and the National Pharmaceutical Pricing Authority (NPPA) regulate its pricing to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for fexofenadine have expired, leading to a competitive generic market. This has facilitated the entry of multiple manufacturers, including Indian exporters, into global markets.

In January 2023, the EMA's PSUSA for fexofenadine resulted in a variation to the marketing authorization terms, emphasizing the need for continuous monitoring of safety data. (ema.europa.eu)

In August 2025, the MHRA issued a Class 4 Medicines Defect Notification due to a barcode error on certain batches of fexofenadine hydrochloride 120 mg tablets, highlighting the importance of accurate labeling and quality control. (gov.uk)

These developments underscore the dynamic nature of the regulatory landscape for fexofenadine and the necessity for exporters to stay informed and compliant with evolving standards.

India's pharmaceutical industry, including the production of Fexofenadine, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 60–70% of these critical components are sourced from China, highlighting a significant dependency. This reliance poses a risk, as any disruption in the supply chain from China can directly impact the availability and production of Fexofenadine in India.

Recent geopolitical tensions have exacerbated this vulnerability. In February 2026, military escalations in the Middle East led to the closure of the Strait of Hormuz, a critical maritime route for global trade. This disruption has caused significant delays and increased costs in shipping, affecting the timely import of APIs and KSMs into India. Consequently, the production schedules for Fexofenadine have been adversely affected, leading to potential shortages in export markets.

The export market for Fexofenadine from India is notably concentrated. The top five exporters—Granules India Limited, Ind Swift Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd, and Sun Pharmaceutical Industries Limited—collectively account for 62.4% of the total export value. Granules India Limited alone holds a 16.1% share, amounting to $17.7 million USD. This high level of supplier concentration introduces a single-source risk; any operational or financial issues within these key companies could disrupt the global supply of Fexofenadine.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base for Fexofenadine remains to be fully realized.

The closure of the Strait of Hormuz in February 2026, due to escalating conflicts involving Iran, the United States, and Israel, has had profound implications for global shipping routes. This strategic chokepoint handles approximately 20% of the world's daily oil supply, and its blockade has led to significant disruptions in maritime traffic. Shipping companies have been forced to reroute vessels around the Cape of Good Hope, adding 10–14 days to transit times and increasing costs by up to $1 million per trip. These delays and cost escalations have directly impacted the export logistics of Fexofenadine, leading to potential supply shortages in key markets.

Additionally, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have issued alerts regarding potential shortages of critical medications due to these shipping disruptions. While Fexofenadine has not been specifically mentioned, the broader implications for pharmaceutical supply chains are evident.

To address the identified risks in the Fexofenadine supply chain, the following actionable steps are recommended:

• Diversify API and KSM Sources: Reduce dependency on Chinese imports by developing alternative sources for APIs and KSMs, including domestic production and sourcing from other countries.

• Enhance Supplier Base: Encourage the growth of smaller pharmaceutical manufacturers to reduce the current high supplier concentration and mitigate single-source risks.

• Strengthen Domestic Manufacturing: Accelerate the implementation and effectiveness of the PLI scheme to bolster domestic production capabilities for APIs and KSMs.

• Develop Contingency Logistics Plans: Establish alternative shipping routes and logistics strategies to navigate around geopolitical hotspots like the Strait of Hormuz, ensuring uninterrupted supply chains.

• Monitor Geopolitical Developments: Implement a robust monitoring system for geopolitical events that could impact supply chains, allowing for proactive risk management and response.

RISK_LEVEL: HIGH

Given the significant dependencies on imported raw materials, high supplier concentration, and current geopolitical disruptions affecting critical shipping routes, the supply chain risk for Fexofenadine exported from India is assessed as high.